1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance

 
• By Jung Won Shin

Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.

License agreement
Yuhan Licenses Out Novel EGFR-TKI To Janssen • Source: Shutterstock

Yuhan Corp. has reached a license and co-development agreement with Janssen Biotech Inc. for the South Korean company's novel third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib, in a massive deal worth as much as $1.25bn in total plus double-digit sales royalties to Yuhan along with the drug's originators.

The move marks another long-awaited mega licensing alliance between South Korean and global pharma firms, and adds to the increasing international recognition of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

More from Focus On Asia